Compare

Lonza Group AG/Fr. LONN

1D1W1M3M6MYTD1Y5YMAX

About Lonza Group AG

Lonza Group AG is a Swiss multinational chemicals and biotechnology company headquartered in Basel, Switzerland. The company operates primarily in the life sciences sector, offering products and services for pharmaceutical and biotechnology companies, including custom development and manufacturing of active pharmaceutical ingredients, cell and gene therapies, and bioscience solutions. Founded in 1897, Lonza has a significant global presence with numerous production and research facilities worldwide. The company's strategic positioning lies in its comprehensive offering that supports pharmaceutical companies from early-stage development through commercialization, leveraging advanced technologies and extensive expertise in biologics.
Ticker
Fr. LONN
Sector
Health
Primary listing
XSWX
Employees
20,141
Headquarters
Basel, Switzerland
Website
www.lonza.com

Lonza Group AG Metrics

BasicAdvanced
CHF 44B
-
-CHF 1.57
0.81
CHF 5.00
0.40%

Bulls say / Bears say

Lonza lifted its 2026 core EBITDA margin outlook to 33–34% and now targets a high-thirties margin over the medium term, alongside 10–13% organic sales growth. If delivered, this would support earnings growth ahead of sales. (The Wall Street Journal, Deutsche Börse)
Specialized Modalities returned to strong growth in the first half: sales rose 22.6% at constant exchange rates and its core EBITDA margin improved by 10.7 percentage points. This adds evidence of momentum beyond the core biologics business. (Lonza)
A long-term collaboration with a major pharmaceutical company supports Lonza’s planned commercial-scale ADC filling line in Stein. The project could strengthen its integrated offering in a growing, higher-value drug segment. (Lonza)
Lonza expects growth and profitability to moderate in the second half of 2026 as business activity is phased differently and comparisons become tougher; foreign exchange is also expected to reduce annual sales growth by 2–3 percentage points. That leaves less room for any short-term results surprise. (Reuters, Lonza)
Sales at the Vacaville site are expected to stay broadly flat through 2028, with more meaningful growth only afterwards. That delays the contribution from a key acquired facility and leaves near-term growth reliant on other sites. (Reuters, Investing.com)
Lonza spent CHF 0.5 billion on capital expenditure in the first half, equal to 15.7% of sales, and expects investment intensity to remain in the mid-to-high teens. This heavy spending may weigh on near-term cash generation while new capacity is built and ramps up. (Lonza)
Data summarised monthly by Lightyear AI. Last updated on 15 Oct 2026.

Funds containing Lonza Group AG

AllEURUSD
Funds
Fund name
Fund size
Fr. LONN weighting
iShares MSCI Europe Health Care Sector€ESIH
€890M2.87%
iShares MSCI Europe Health Care Sector£ESIH
€890M2.87%
iShares STOXX Europe 600 Health Care€EXV4
€709M2.74%
iShares MSCI Europe SRI£IESG
€3.2B2.02%
iShares MSCI Europe SRI€IESE
€3.2B2.02%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.